Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies

被引：0
|
作者：
Rudofsky, G. [1 ]
Bodholdt, U. [2 ]
Catarig, A. -M. [3 ]
Ekberg, N. Rajamand [4 ]
Erhan, U. [3 ]
Liutkus, J. F. [5 ]
Tariq, M. [6 ]
Holmes, P. [7 ]
机构：
[1] Kantonssp, Olten, Switzerland
[2] Kastrup Doctors, Copenhagen, Denmark
[3] Novo Nordisk AS, Soborg, Denmark
[4] Karolinska Inst, Stockholm, Sweden
[5] Joanne F Liutkus Med Profess Corp, Cambridge, ON, Canada
[6] Novo Nordisk Serv Ctr India Private Ltd, Bangalore, Karnataka, India
[7] St Georges Med Practice, Darlington, Durham, England
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
447
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [21] Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
    Visaria, Jay
    Uzoigwe, Chioma
    Swift, Caroline
    Dang-Tan, Tam
    Paprocki, Yurek
    Willey, Vincent J.
    CLINICAL THERAPEUTICS, 2021, 43 (05) : 808 - 821
  • [22] Mobile Health Application as a Real-World Data Resource: SelfRecorded Weight Reduction with Once-Weekly Semaglutide
    Bodholdt, Ulrik
    Birot, Sophie
    Catarig, Andrei-Mircea
    Erhan, Umut
    Knop, Filip K.
    DIABETES, 2021, 70
  • [23] Safety profile of once-weekly subcutaneous semaglutide in a real-world adult population with type 2 diabetes
    Yale, J. -F.
    Major-Pedersen, A.
    Catarig, A. -M.
    Jain, R. G.
    Menzen, M.
    Holmes, P.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S339 - S340
  • [24] A COST OF CONTROL ANALYSIS OF ONCE-WEEKLY SUBCUTANEOUS SEMAGLUTIDE VERSUS DULAGLUTIDE FOR BRINGING PATIENTS TO TREATMENT TARGETS IN CHINA
    Zhen, R.
    Gu, Z.
    Shen, Y.
    Chen, L.
    VALUE IN HEALTH, 2022, 25 (07) : S350 - S350
  • [25] Real-World Use of Once-Weekly Semaglutide in Thai Patients With Type 2 Diabetes Mellitus in a Private Hospital Setting
    Thewjitcharoen, Yotsapon
    Yenseung, Nalin
    Butadej, Siriwan
    Nakasatien, Soontaree
    Chotwanvirat, Phawinpon
    Chatchomchuan, Waralee
    Wanothayaroj, Ekgaluck
    Krittiyawong, Sirinate
    Himathongkam, Thep
    JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES, 2023, 38 (01): : 21 - 28
  • [26] Safety Profile of Once-Weekly Subcutaneous Semaglutide in a Real-World Adult Population with T2D
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES, 2023, 72
  • [27] Real-World Evaluation of Once-Weekly Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus in Spain (SEMA-RW Study)
    Mateos, Irene Caballero
    de Lucas, Maria Dolores Garcia
    Doulatram-Gamgaram, Viyey Kishore
    Moreno-Moreno, Paloma
    Jimenez-Millan, Ana Isabel
    Botana-Lopez, Manuel
    Merino-Torres, Juan Francisco
    Soto-Gonzalez, Alfonso
    Fernandez-Garcia, Jose Carlos
    Morales-Portillo, Cristobal
    NUTRIENTS, 2024, 16 (15)
  • [28] Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a US Commercially Insured and Medicare Advantage Population
    Visaria, Jay
    Uzoigwe, Chioma
    Swift, Caroline
    Paprocki, Yurek M.
    Willey, Vincent
    DIABETES, 2020, 69
  • [29] Mobile health application as a real-world data resource: self-recorded weight reduction with once-weekly semaglutide
    Bodholdt, U.
    Birot, S.
    Catarig, A. -M.
    Erhan, U.
    Knop, F. K.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 232 - 233
  • [30] Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a US Commercially Insured and Medicare Advantage Population
    Willey, Vincent
    Shivappa, Nitin
    Noone, Joshua
    Swift, Caroline
    Du, Simo
    Yurek, M. Paprocki .
    Tan, Hiangkiat
    DIABETES, 2021, 70
12345